PHARMAC
TE PĀTAKA WHAIORANGA

Specialist Advisory Committees

Objective advice to Pharmac

www.pharmac.govt.nz

Cardiovascular Advisory Committee Provisional recommendations 23 October 2026

Pharmac is piloting a new approach which will allow people to understand the advice we get, within 30 business days of advisory committee meetings.
More information about provisional recommendations is on Pharmac's website

We are releasing provisional recommendations only at this time, which share the high-level outcome of the advice recommendation. Further information, which will explain the recommendation, will be shared when the full meeting record is completed. Applicants / suppliers are given the opportunity to withhold the provisional recommendation until more information is available.

The provisional recommendations share the funding recommendation outcomes from the meeting. Further information and updates for all applications discussed will be available in the full meeting record.

The Cardiovascular Advisory Committee also discussed the Direct Acting Anticoagulants in preparation for a possible procurement activity, various other applications under assessment and correspondence received regarding polypills for cardiovascular risk reduction.

Summary of Provisional Recommendations

Pharmaceutical and Indication	Provisional Recommendation
Semaglutide for the treatment of established cardiovascular disease (CV) in individuals with high Body Mass Index (BMI) ≥27 kg/m2, within the context of treatments for cardiovascular disease, subject to special authority criteria	High priority
Semaglutide for the treatment of established cardiovascular disease (CV) in individuals with moderate to severe obesity (BMI >35), within the context of treatments for cardiovascular disease, subject to special authority criteria	High priority
Mavacamten for the treatment of obstructive hypertrophic cardiomyopathy, symptomatic, 2nd line, within the context of treatments for cardiovascular disease, subject to special authority criteria	High priority

*Withheld provisional recommendation – the applicant / supplier has requested the recommendation not be released until full record is available.

More information about the agenda items considered at the recent Cardiovascular Advisory Committee meeting can be found on the Pharmac website here.

Released 2 November 2026